GSK's breast cancer drug Tyverb gets EU marketing authorization for extra indication

15 August 2013

UK pharma major GlaxoSmithKline (LSE: GSK) has received marketing authorization from the European Commission for an additional indication of its cancer drug Tyverb (lapatinib), which is sold as Tykerb in the USA.

The new indication is for Tyverb to be used in combination with trastuzumab for adult patients with breast cancer whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.

Paolo Paoletti, president, GlaxoSmithKline Oncology, said: “Today’s announcement is important for women with this specific type of metastatic breast cancer, who will have now a new treatment option. The combination of Tyverb and trastuzumab, which is chemotherapy-free, has the potential to make a positive impact on the care and survival of these patients.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical